Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 722
- Registration Number
- NCT00783211
Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 131
- Registration Number
- NCT00783133
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)
Phase 4
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 100
- Registration Number
- NCT00783458
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00783354
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 250
- Registration Number
- NCT00782184
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 728
- Registration Number
- NCT00783146
Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 340
- Registration Number
- NCT00783237
Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT00780403
A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 455
- Registration Number
- NCT00779545
Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 442
- Registration Number
- NCT00778999